Expert Opinion On Drug Safety
Scope & Guideline
Empowering Researchers with Critical Drug Safety Insights
Introduction
Aims and Scopes
- Pharmacovigilance and Drug Safety Analysis:
The journal emphasizes the importance of pharmacovigilance, aiming to monitor, assess, and understand adverse drug reactions and safety signals associated with various medications. - Clinical Safety Evaluations:
It provides comprehensive evaluations of drug safety through systematic reviews, meta-analyses, and real-world studies, offering insights into the efficacy and safety of drugs across multiple therapeutic areas. - Risk-Benefit Assessments:
The journal focuses on the balance between the therapeutic benefits of drugs and their potential risks, providing guidance for clinicians in making informed treatment decisions. - Emerging Drug Safety Concerns:
It addresses new and emerging safety concerns related to drugs, particularly in the context of novel therapies and changing treatment paradigms. - Real-World Evidence Integration:
The journal integrates real-world evidence to enhance understanding of drug safety in diverse populations and clinical settings, ensuring that findings are applicable to everyday medical practice.
Trending and Emerging
- Real-World Evidence and Data Mining:
There is a growing emphasis on utilizing real-world evidence and advanced data mining techniques to uncover adverse drug reactions and safety signals, reflecting a shift towards more data-driven approaches in pharmacovigilance. - Machine Learning and Artificial Intelligence in Drug Safety:
The integration of machine learning and AI technologies in pharmacovigilance is trending, with studies focusing on their potential to improve signal detection and risk assessment in drug safety. - Patient-Centric Pharmacovigilance:
An emerging focus on incorporating patient perspectives, experiences, and reported outcomes into drug safety evaluations is evident, aiming to enhance the relevance and applicability of findings. - Safety of Novel Therapeutics and Biologics:
Research is increasingly directed towards the safety profiles of novel therapeutics, including biologics and targeted therapies, particularly in oncology and immunology, reflecting the rapid advancement of these treatment modalities. - Long-Term Safety and Post-Marketing Surveillance:
There is a heightened interest in long-term safety studies and post-marketing surveillance, emphasizing the need to monitor drugs after they have been approved and widely prescribed.
Declining or Waning
- Traditional Pharmacovigilance Methods:
There is a noticeable decline in studies focusing solely on traditional pharmacovigilance methods, as the field shifts towards more innovative and technology-driven approaches such as machine learning and big data analytics. - Generalized Drug Safety Reviews:
The trend towards more specialized and targeted safety evaluations has led to a decrease in broad, generalized reviews of drug safety, which may have been more common in earlier publications. - Historical Drug Safety Studies:
Research focusing on historical data or older medications is becoming less prevalent, as the journal increasingly prioritizes contemporary drugs and therapies. - Single-Agent Safety Studies:
There is a waning interest in studies examining the safety of single-agent therapies, with a growing focus on combination therapies and polypharmacy, especially in complex patient populations. - Pharmacovigilance in Non-Pharmaceutical Contexts:
The journal has seen a reduction in articles addressing pharmacovigilance in non-pharmaceutical contexts, such as dietary supplements or herbal products, which were previously more common.
Similar Journals
DRUGS & THERAPY PERSPECTIVES
Catalyzing Change in the World of Pharmacology and TherapyDRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Elevating Standards in Drug Safety and EfficacyBritish Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.
BMC Pharmacology & Toxicology
Innovating the future of pharmacological sciences.Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.
International Journal of Clinical Pharmacy
Enhancing Therapeutic Outcomes with Cutting-Edge InsightsThe International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.
Current Drug Safety
Elevating Standards in Drug Safety EvaluationCurrent Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.
CLINICAL DRUG INVESTIGATION
Pioneering research for a healthier tomorrow.CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.
AMERICAN JOURNAL OF THERAPEUTICS
Fostering Discourse in Therapeutics for Better OutcomesThe American Journal of Therapeutics is a prominent academic journal published by Lippincott Williams & Wilkins, specializing in the fields of medicine and pharmacology. With a rich history originating from 1960 and a commitment to advancing therapeutic knowledge through peer-reviewed research, this journal serves as a vital resource for professionals, researchers, and students alike. Its strong impact factor, alongside its classification in the Q2 and Q3 quartiles for diverse categories in medicine and pharmacology, underscores its significance in the academic community. The journal engages with the latest findings and innovations in therapeutic approaches, offering a platform for discussion and dissemination of research that addresses critical healthcare challenges. Although it operates under a traditional subscription model, the journal aims to foster open discourse within the therapeutic landscape, making it essential reading for those dedicated to enhancing patient care and pharmaceutical practices.
Therapeutic Advances in Drug Safety
Exploring New Horizons in Pharmacological SafetyTherapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.
PHARMAZIE
Empowering innovation in pharmaceutical sciences.PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.
Therapeutics and Clinical Risk Management
Championing open access to critical therapeutic knowledge.Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.